NZ747821A - Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof - Google Patents
Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereofInfo
- Publication number
- NZ747821A NZ747821A NZ74782113A NZ74782113A NZ747821A NZ 747821 A NZ747821 A NZ 747821A NZ 74782113 A NZ74782113 A NZ 74782113A NZ 74782113 A NZ74782113 A NZ 74782113A NZ 747821 A NZ747821 A NZ 747821A
- Authority
- NZ
- New Zealand
- Prior art keywords
- isoquinoline
- tetrahydro
- dihydro
- prmt5 inhibitors
- compounds
- Prior art date
Links
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 title 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150097768 prmt5 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract 2
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745485P | 2012-12-21 | 2012-12-21 | |
| US201361790525P | 2013-03-15 | 2013-03-15 | |
| NZ70908413 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ747821A true NZ747821A (en) | 2019-09-27 |
Family
ID=68318665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ74782113A NZ747821A (en) | 2012-12-21 | 2013-12-20 | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ747821A (en) |
-
2013
- 2013-12-20 NZ NZ74782113A patent/NZ747821A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500163A1 (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| MX2015012850A (en) | Arginine methyltransferase inhibitors and uses thereof. | |
| WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| MD4800B1 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
| EA201691803A1 (en) | HUMAN PLASMA KALLIKREIN INHIBITORS | |
| MX2013012776A (en) | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors. | |
| MY172924A (en) | Neprilysin inhibitors | |
| JO3115B1 (en) | Pyridazinone Compounds and Their Use as DAAO Inhibitors | |
| PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| MX363551B (en) | Pyrazine kinase inhibitors. | |
| MX2015010619A (en) | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer. | |
| PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| NZ747821A (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2021 BY COMPUTER PACKAGES INC Effective date: 20201201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2022 BY COMPUTER PACKAGES INC Effective date: 20211130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2023 BY COMPUTER PACKAGES INC Effective date: 20221130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2024 BY CPA GLOBAL Effective date: 20231102 |